![Martine Zimmermann](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Patrimonio netto: 1 M $ in data 31/05/2026
Martine Zimmermann currently works at Ligand Pharmaceuticals, Inc., as Independent Director from 2023 and Inventiva SA, as EVP-Regulatory Affairs & Quality Assurance from 2025.
Dr. Zimmermann also formerly worked at Caelum Biosciences, Inc., as Director from 2019 to 2021, Alexion Pharmaceuticals, Inc., as Senior VP & Head-Global Regulatory Affairs from 2016 to 2023, and Ipsen Biopharmaceuticals, Inc., as SVP, Head-Regulatory Affairs, R&D Quality.
Dr. Zimmermann received her doctorate degree from the University of Strasbourg and doctorate degree from Louis Pasteur University.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 05/06/2026 | 5.097 ( 0,03% ) | 1 M $ | 31/05/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| INVENTIVA | Consigliere Generale | 09/07/2025 |
| LIGAND PHARMACEUTICALS INCORPORATED | Direttore/Membro del Consiglio | 26/09/2023 |
| Società | Posizione | Fine |
|---|---|---|
| ALEXION PHARMACEUTICALS, INC. | Consigliere Generale | 01/02/2023 |
Caelum Biosciences, Inc.
 Caelum Biosciences, Inc. BiotechnologyHealth Technology Operates as clinical stage biotechnology company that develops treatments for AL amyloidosis, rare and life-threatening hematologic disorders | Direttore/Membro del Consiglio | 01/01/2021 |
Ipsen Biopharmaceuticals, Inc.
 Ipsen Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as biopharmaceutical company | Consigliere Generale | - |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 7 |
|---|---|
Ligand Pharmaceuticals, Inc.
 Ligand Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which develops and sells drug development technologies | Health Technology |
Alexion Pharmaceuticals, Inc.
 Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company that develops life-changing therapies for people living with rare disorders | Health Technology |
University of Strasbourg
 University of Strasbourg Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Ipsen Biopharmaceuticals, Inc.
Ipsen Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as biopharmaceutical company | Health Technology |
Inventiva SA
 Inventiva SA BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company that develops oral small molecule therapies for the treatment of MASH and other diseases | Health Technology |
Caelum Biosciences, Inc.
Caelum Biosciences, Inc. BiotechnologyHealth Technology Operates as clinical stage biotechnology company that develops treatments for AL amyloidosis, rare and life-threatening hematologic disorders | Health Technology |
Louis Pasteur University
 Louis Pasteur University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale
